Delving into the Latest Updates on Kuros Biosciences BV with Synapse

概览

排名前五的药物类型	数量

生物药	1

排名前五的靶点	数量

PTH1R(甲状旁腺激素受体)	1

关联

1

项与 Kuros Biosciences BV 相关的药物

KUR-113

靶点

PTH1R

作用机制

PTH1R激动剂 [+1]

在研机构

Kuros Biosciences BV [+1]

原研机构

Kuros Biosciences Ltd.

在研适应症

椎间盘退化 [+1]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

4

项与 Kuros Biosciences BV 相关的临床试验

NCT04679844 / Not yet recruitingN/A

A Prospective, Randomized, Multi-Center Study to Assess the Safety and Performance of MagnetOs Putty Compared to Demineralized Bone Matrix Mixed With Autograft in Patients Undergoing One to Two-Level Instrumented Posterolateral Lumbar/Thoracolumbar Fusion (PLF)

This is a phase IV post-marketing study for MagnetOs Putty. MagnetOs Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery.
In this study, MagnetOs Putty will be used according to the latest U.S. Instructions For Use, specifically as a bone graft extender mixed with autograft in a 1:1 vol.% in the posterolateral spine.

开始日期2024-05-01

申办/合作机构

Kuros Biosurgery AG

[+2]

NCT04128852 / WithdrawnN/A

A Prospective, Single Arm, Single-center Study to Assess the Safety and Performance of MagnetOs Putty in Patients Undergoing Single/Two-level Lateral Lumbar Interbody Fusion

This study is a post-marketing clinical follow-up study for MagnetOs Putty. MagnetOs Putty is a synthetic bone-like material which is routinely used by surgeons as a treatment for patients with degenerative disc disease who will undergo surgery for spinal fusion (extreme lateral interbody fusion (XLIF). MagnetOs Putty will be used according to the instructions for use.

开始日期2020-11-11

申办/合作机构

Kuros Biosurgery AG

[+3]

NCT04294004 / Active, not recruiting临床2期

A Prospective, Randomized and Non-randomized, Controlled, Single-blind and Open-label, Dose-finding, Multi-center, Parallel Group Study of Safety/Efficacy of KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion

The purpose of this study is to evaluate the safety and efficacy of KUR-113 Bone Graft (TGplPTH1-34 in fibrin) compared to local autograft for the treatment of Degenerative Disk Disease (DDD).

开始日期2020-08-27

申办/合作机构

Kuros Biosurgery AG

[+2]

100 项与 Kuros Biosciences BV 相关的临床结果

登录后查看更多信息

0 项与 Kuros Biosciences BV 相关的专利（医药）

登录后查看更多信息

3

项与 Kuros Biosciences BV 相关的文献（医药）

Biomaterials Science2区 · 工程技术

Variation of the bone forming ability with the physicochemical properties of calcium phosphate bone substitutes

2区 · 工程技术

Article

作者: Bao, Chongyun ; de Bruijn, Joost D. ; Barbieri, Davide ; Duan, Rongquan ; Luo, Xiaoman ; Weng, Jie ; Yuan, Huipin

The submicron-scaled surface structure triggers osteoinduction in CaPsviamechanotransduction, rather than protein adsorption, surface mineralization and calcium ion release.

Bone morphogenetic protein 4 gene therapy in mice inhibits myeloma tumor growth, but has a negative impact on bone

作者: U. Smith ; M. Westhrin ; H. Hella ; T. Standal ; A. M. Sponaas ; F. Bosch ; G. Buene ; B. Stordal ; S. H. Moen ; M. Zahoor ; J. D. de Bruijn ; R. W. Groen ; T. Holien ; A. Martens ; A. Sundan ; H. Yuan

AbstractMultiple myeloma is characterized by accumulation of malignant plasma cells in the bone marrow. Most patients suffer from an osteolytic bone disease, caused by increased bone degradation and reduced bone formation. Bone morphogenetic protein 4 (BMP4) is important for both pre- and postnatal bone formation and induces growth arrest and apoptosis of myeloma cells. BMP4-treatment of myeloma patients could have the potential to reduce tumor growth and restore bone formation. We therefore explored BMP4 gene therapy in a human-mouse model of multiple myeloma where humanized bone scaffolds were implanted subcutaneously in RAG2−/−γC−/−mice. Mice were treated with adeno-associated virus serotype 8 BMP4 vectors (AAV8-BMP4) to express BMP4 in the liver. When mature BMP4 was detectable in the circulation, myeloma cells were injected into the scaffolds and tumor growth was examined by weekly imaging. Strikingly, the tumor burden was reduced in AAV8-BMP4 mice compared with the AAV8-CTRL mice, suggesting that increased circulating BMP4 reduced tumor growth. BMP4-treatment also prevented bone loss in the scaffolds, most likely due to reduced tumor load. To delineate the effects of BMP4 overexpression on bone per se, without direct influence from cancer cells, we examined the unaffected, non-myeloma femurs by μCT. Surprisingly, the AAV8-BMP4 mice had significantly reduced trabecular bone volume, trabecular numbers, as well as significantly increased trabecular separation compared with the AAV8-CTRL mice. There was no difference in cortical bone parameters between the two groups. Taken together, BMP4 gene therapy inhibited myeloma tumor growth, but also reduced the amount of trabecular bone in mice. Our data suggest that care should be taken when considering using BMP4 as a therapeutic agent.

Journal of Materials Chemistry B

Macrophage polarization plays roles in bone formation instructed by calcium phosphate ceramics

Article

作者: Guo, Xiaodong ; Xiao, Yu ; de Bruijn, Joost D. ; Yuan, Huipin ; Li, Mingzheng ; Qi, Wenting ; Bao, Chongyun ; Wu, Zhenzhen

TCPs recruited more macrophages which polarized towards tissue repair macrophages to create a favourable osteo-immune environment for material-instructed bone formation.

100 项与 Kuros Biosciences BV 相关的药物交易

登录后查看更多信息

100 项与 Kuros Biosciences BV 相关的转化医学

登录后查看更多信息